Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:KNSA NASDAQ:NRIX NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.83-4.6%$2.08$0.87▼$6.37$285.92M0.99881,660 shs152,303 shsKNSAKiniksa Pharmaceuticals International$35.98-1.6%$32.03$17.82▼$37.34$2.67B0.2661,330 shs40,145 shsNRIXNurix Therapeutics$8.41-3.1%$10.58$8.18▼$29.56$643.70M2.1858,399 shs169,547 shsNTLAIntellia Therapeutics$11.82+2.1%$11.65$5.90▼$23.76$1.26B2.284.09 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+7.64%+7.25%+31.56%+94.74%-50.91%KNSAKiniksa Pharmaceuticals International-1.46%-0.03%+9.53%+30.81%+44.73%NRIXNurix Therapeutics-4.09%-10.62%-18.05%-23.88%-65.04%NTLAIntellia Therapeutics+1.31%-2.28%+5.28%+20.77%-47.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.83-4.6%$2.08$0.87▼$6.37$285.92M0.99881,660 shs152,303 shsKNSAKiniksa Pharmaceuticals International$35.98-1.6%$32.03$17.82▼$37.34$2.67B0.2661,330 shs40,145 shsNRIXNurix Therapeutics$8.41-3.1%$10.58$8.18▼$29.56$643.70M2.1858,399 shs169,547 shsNTLAIntellia Therapeutics$11.82+2.1%$11.65$5.90▼$23.76$1.26B2.284.09 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+7.64%+7.25%+31.56%+94.74%-50.91%KNSAKiniksa Pharmaceuticals International-1.46%-0.03%+9.53%+30.81%+44.73%NRIXNurix Therapeutics-4.09%-10.62%-18.05%-23.88%-65.04%NTLAIntellia Therapeutics+1.31%-2.28%+5.28%+20.77%-47.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1747.49% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1714.42% UpsideNRIXNurix Therapeutics 2.88Moderate Buy$29.07245.88% UpsideNTLAIntellia Therapeutics 2.56Moderate Buy$27.11129.46% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, KNSA, NRIX, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/13/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/11/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $60.008/8/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$50.00 ➝ $45.008/8/2025NTLAIntellia TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $21.008/8/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.007/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.507/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/15/2025NRIXNurix TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$17.00 ➝ $16.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$81.13M3.52N/AN/A$1.29 per share2.19KNSAKiniksa Pharmaceuticals International$529.33M5.04N/AN/A$6.60 per share5.45NRIXNurix Therapeutics$88.38M7.27N/AN/A$7.44 per share1.13NTLAIntellia Therapeutics$52.86M24.00N/AN/A$8.56 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04899.97143.92N/A0.90%1.05%0.80%11/4/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)Latest ALEC, KNSA, NRIX, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/10/2025Q3 2025NRIXNurix Therapeutics-$0.84N/AN/AN/A$16.06 millionN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16NRIXNurix TherapeuticsN/A6.826.82NTLAIntellia TherapeuticsN/A5.195.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%KNSAKiniksa Pharmaceuticals International53.95%NRIXNurix TherapeuticsN/ANTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%KNSAKiniksa Pharmaceuticals International53.48%NRIXNurix Therapeutics7.40%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableNTLAIntellia Therapeutics600107.35 million104.02 millionOptionableALEC, KNSA, NRIX, and NTLA HeadlinesRecent News About These CompaniesA Turning Point for Intellia Therapeutics: Clinical Progress and Investor Confidence Build MomentumSeptember 15 at 5:34 AM | aktiencheck.deAIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $27.11 Consensus PT from BrokeragesSeptember 15 at 2:30 AM | americanbankingnews.com2 More Stocks With 1,000% UpsideSeptember 14 at 12:00 PM | investorplace.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 14 at 2:13 AM | marketbeat.comZacks Research Issues Positive Outlook for NTLA EarningsSeptember 12, 2025 | marketbeat.comZacks Research Has Positive Estimate for NTLA Q3 EarningsSeptember 12, 2025 | americanbankingnews.comCathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%September 11, 2025 | fool.comIntellia Therapeutics, Inc. $NTLA Shares Sold by Polar Asset Management Partners Inc.September 9, 2025 | marketbeat.comGranahan Investment Management LLC Increases Stock Position in Intellia Therapeutics, Inc. $NTLASeptember 8, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 8, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street ZenSeptember 8, 2025 | americanbankingnews.comRussell Investments Group Ltd. Cuts Stock Position in Intellia Therapeutics, Inc. $NTLASeptember 7, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5% - Should You Buy?September 5, 2025 | marketbeat.comPDT Partners LLC Buys 132,638 Shares of Intellia Therapeutics, Inc. $NTLASeptember 4, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 169.7K shares of Intellia Therapeutics todaySeptember 3, 2025 | msn.comArmistice Capital LLC Makes New Investment in Intellia Therapeutics, Inc. $NTLASeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 62,936 Shares of Intellia Therapeutics, Inc. $NTLASeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Cuts Stake in Intellia Therapeutics, Inc. $NTLASeptember 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. $NTLA Shares Acquired by Invesco Ltd.September 3, 2025 | marketbeat.comWhy big players are pouring millions in THIS biotech stockSeptember 1, 2025 | invezz.comISecond Line Capital LLC Sells 51,423 Shares of Intellia Therapeutics, Inc. $NTLASeptember 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, KNSA, NRIX, and NTLA Company DescriptionsAlector NASDAQ:ALEC$2.82 -0.14 (-4.56%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$35.98 -0.58 (-1.59%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Nurix Therapeutics NASDAQ:NRIX$8.40 -0.27 (-3.06%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Intellia Therapeutics NASDAQ:NTLA$11.82 +0.25 (+2.12%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
